Lexaria Bioscience (NASDAQ:LEXX) Stock Price Down 1.8% – Should You Sell?

Posted by Brian Himes on Jun 11th, 2026

Lexaria Bioscience Corp. (NASDAQ:LEXX – Get Free Report)’s share price was down 1.8% on Wednesday . The stock traded as low as $0.6510 and last traded at $0.6560. Approximately 117,002 shares changed hands during trading, an increase of 32% from the average daily volume of 88,496 shares. The stock had previously closed at $0.6680.

Analyst Ratings Changes

Separately, Weiss Ratings raised shares of Lexaria Bioscience from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, April 22nd. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Lexaria Bioscience presently has a consensus rating of “Hold” and a consensus target price of $1.50.

Check Out Our Latest Analysis on Lexaria Bioscience

Lexaria Bioscience Stock Down 1.8%

The company’s fifty day moving average is $0.77 and its two-hundred day moving average is $0.78. The firm has a market capitalization of $16.26 million, a price-to-earnings ratio of -1.40 and a beta of 0.35.

Lexaria Bioscience (NASDAQ:LEXX – Get Free Report) last announced its quarterly earnings data on Monday, April 13th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.04. The business had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.05 million. On average, equities research analysts expect that Lexaria Bioscience Corp. will post -0.26 EPS for the current year.

Hedge Funds Weigh In On Lexaria Bioscience

Several large investors have recently bought and sold shares of LEXX. Virtu Financial LLC acquired a new stake in Lexaria Bioscience in the third quarter worth $28,000. Byrne Asset Management LLC increased its position in shares of Lexaria Bioscience by 236.8% during the fourth quarter. Byrne Asset Management LLC now owns 105,500 shares of the company’s stock worth $65,000 after acquiring an additional 74,180 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Lexaria Bioscience by 25.7% during the fourth quarter. Geode Capital Management LLC now owns 219,718 shares of the company’s stock worth $136,000 after acquiring an additional 44,939 shares in the last quarter. 13.06% of the stock is currently owned by institutional investors and hedge funds.

Lexaria Bioscience Company Profile

(Get Free Report)

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a biotech company specializing in the development and commercialization of proprietary drug delivery platforms. The company’s flagship technology, DehydraTECH, is designed to improve the oral bioavailability, onset time and overall efficiency of active molecules such as cannabinoids, nicotine and other lipophilic compounds. Lexaria’s platform seeks to address absorption challenges commonly associated with oral delivery by enhancing the rate and extent at which compounds enter the bloodstream.

Founded in 2014 and headquartered in Kelowna, British Columbia, Lexaria operates in the pharmaceutical, nutraceutical and consumer product markets.